| CAS NO: | 1801344-14-8 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 1801344-14-8 |
| 别名 | CA-4948 |
| Canonical SMILES | O=C(C1=COC(C2=CC=NC(C)=C2)=N1)NC3=C(N4CC[C@@H](O)C4)N=C5C(OC(N6CCOCC6)=N5)=C3 |
| 分子式 | C24H25N7O5 |
| 分子量 | 491.5 |
| 溶解度 | DMSO: soluble |
| 储存条件 | -20буC |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Emavusertib is an inhibitor of IL-1 receptor-associated kinase 4 (IRAK4; IC50= 31.7 nM).1It is selective for IRAK4 over FMS-related tyrosine kinase 3 (FLT3), cyclin-dependent kinase 2 (Cdk2), Aurora A kinase, glycogen synthase kinase 3β (GSK3β), and muscle-associated receptor tyrosine kinase (MUSK) at 1 µM. Emavusertib inhibits IL-6 release mediated by toll-like receptor 2 (TLR2), TLR5, or IL-1 receptor (IL-1R) in isolated human whole blood (IC50s = 989, 696, and 1,375 nM, respectively).In vivo, emavusertib (25-200 mg/kg) reduces tumor volume in an OCI-Ly3 diffuse large B cell lymphoma (DLBCL) mouse xenograft model. 1.Gummadi, V.R., Boruah, A., Ainan, B.R., et al.Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignanciesACS Med. Chem. Lett.11(12)2374-2381(2020) |
m.cnreagent.com